Actively Recruiting
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
Led by Mayo Clinic · Updated on 2025-08-08
50
Participants Needed
1
Research Sites
73 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this research is to study the effects of intravenous ketamine infusions for the treatment of patients with depressive symptoms in intensive care unit (ICU).
CONDITIONS
Official Title
A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Has been in the Mayo Clinic Florida ICU for the past 1 week.
- PHQ-9 score of 10 or higher.
- Has one of the following diagnoses: acute myocardial infarction; acute renal failure; chronic obstructive pulmonary disease (COPD); congestive heart failure; end-stage liver disease; requiring intra-aortic balloon pump (IABP) therapy or continuous renal replacement therapy (CRRT); post-bone marrow transplant; acute or chronic hypoxemic respiratory failure; pre- or post- lung, liver or heart transplant; or recent major surgeries such as abdominal aortic aneurysm repair, thoracotomy, or tracheostomy.
You will not qualify if you...
- Poor vital sign stability including hypoxia (O2 < 95%), hypotension (SBP < 90), or hypertension (SBP > 180).
- Heart rate less than 50 or greater than 120, or respiratory rate less than 10 or greater than 30.
- Altered mental status.
- Unwillingness to participate or provide informed consent.
- Allergy to ketamine or diphenhydramine.
- Female of child-bearing age unwilling to provide urine or blood for HCG testing.
- Pregnant or breastfeeding.
- Presence of intracranial mass or vascular lesion.
- History of psychosis or hallucinations.
- Weight greater than 115 kg or less than 45 kg.
- History of increased intracranial pressure or hypertensive hydrocephalus or increased intraocular pressure.
- Acutely psychotic.
- Likely to require chemical or physical restraints.
- History of prolonged QT-interval.
- Current use of medications affecting the N-methyl-D-aspartate receptor system (such as lamotrigine, acamprosate, memantine, riluzole, or lithium).
- In withdrawal from substance abuse or used hallucinogens including cannabis in the last month as confirmed by clinical interview and urine drug screening.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mayo Clinic Florida
Jacksonville, Florida, United States, 32224
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here